Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update

被引：66

作者：

Cheson, Bruce D. ^{[1
]}

Brugger, Wolfram ^{[2
]}

Damaj, Gandhi ^{[3
]}

Dreyling, Martin ^{[4
]}

Kahl, Brad ^{[5
]}

Kimby, Eva ^{[6
]}

Ogura, Michinori ^{[7
]}

Weidmann, Eckhart ^{[8
]}

Wendtner, Clemens-Martin ^{[9
]}

Zinzani, Pier Luigi ^{[10
]}

机构：

[1] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA

[2] Univ Freiburg, Schwarzwald Baar Clin, Villingen Schwenningen, Germany

[3] Univ Basse Normandie, Univ Hosp, Caen, France

[4] Univ Hosp Munich, Med Clin, Munich, Germany

[5] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA

[6] Karolinska Inst, Dept Med Huddinge, Ctr Hematol, Stockholm, Sweden

[7] Tokai Cent Hosp, Dept Hematol, Gifu, Japan

[8] Krankenhaus NW Frankfurt, Dept Hematol & Oncol, Frankfurt, Germany

[9] Univ Munich, Klinikum Schwabing Acad Teaching Hosp, Munich, Germany

[10] Univ Bologna, Inst Hematol, Bologna, Italy

来源：

LEUKEMIA & LYMPHOMA | 2016年 / 57卷 / 04期

关键词：

CLL; NHL; multiple myeloma; Hodgkin; Bendamustine; CHRONIC LYMPHOCYTIC-LEUKEMIA; MULTICENTER PHASE-II; STEM-CELL TRANSPLANTATION; INDOLENT B-CELL; PREVIOUSLY UNTREATED PATIENTS; REFRACTORY MULTIPLE-MYELOMA; NON-HODGKINS-LYMPHOMA; MANTLE-CELL; T-CELL; OPEN-LABEL;

D O I：

10.3109/10428194.2015.1099647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.

引用

页码：766 / 782

页数：17

共 95 条

[31] Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study [J].

Goy, Andre ;

Sinha, Rajni ;

Williams, Michael E. ;

Besisik, Sevgi Kalayoglu ;

Drach, Johannes ;

Ramchandren, Radhakrishnan ;

Zhang, Lei ;

Cicero, Sherri ;

Fu, Tommy ;

Witzig, Thomas E. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3688-+

[32] Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma [J].

Grey-Davies, Elisabeth ;

Bosworth, Jennifer L. ;

Boyd, Kevin D. ;

Ebdon, Caroline ;

Saso, Radovan ;

Chitnavis, Dipti ;

Mercieca, Jane E. ;

Morgan, Gareth J. ;

Davies, Faith E. .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (04) :552-555

[33] Sequential Combined Bypassing Therapy (SCBT) Is Safe and Effective in the Treatment of Unresponsive Bleeding in Adults and Children with Haemophilia and Inhibitors. [J].

Gringeri, Alessandro ;

Fischer, Kathelijn ;

Karafoulidou, Anastasia ;

Klamroth, Robert ;

Fernanda Lopez, Maria ;

Mancuso, Maria Elisa .

BLOOD, 2009, 114 (22) :531-531

[34]

Grzasko N, 2014, CLIN LYMPHOMA MYELOM, V15, P187

[35] Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas [J].

Heider, A ;

Niederle, N .

ANTI-CANCER DRUGS, 2001, 12 (09) :725-729

[36] Bendamustine is effective in T-Cell prolymphocytic leukaemia [J].

Herbaux, Charles ;

Genet, Philippe ;

Bouabdallah, Krimo ;

Pignon, Jean-Michel ;

Debarri, Houria ;

Guidez, Stephanie ;

Betrian, Sarah ;

Leleu, Xavier ;

Facon, Thierry ;

Morschhauser, Franck ;

Damaj, Gandhi ;

Cazin, Bruno ;

Ysebaert, Loic .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (06) :916-919

[37] Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma [J].

Hess, G. ;

Keller, U. ;

Scholz, C. W. ;

Witzens-Harig, M. ;

Atta, J. ;

Buske, C. ;

Kirschey, S. ;

Ruckes, C. ;

Medler, C. ;

van Oordt, C. ;

Klapper, W. ;

Theobald, M. ;

Dreyling, M. .

LEUKEMIA, 2015, 29 (08) :1695-1701

[38] Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [J].

Hess, Georg ;

Herbrecht, Raoul ;

Romaguera, Jorge ;

Verhoef, Gregor ;

Crump, Michael ;

Gisselbrecht, Christian ;

Laurell, Anna ;

Offner, Fritz ;

Strahs, Andrew ;

Berkenblit, Anna ;

Hanushevsky, Orysia ;

Clancy, Jill ;

Hewes, Becker ;

Moore, Laurence ;

Coiffier, Bertrand .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3822-3829

[39] Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial [J].

Jerkeman, Mats ;

Kolstad, Arne ;

Laurell, Anna ;

Raty, Riikka ;

Gronbaek, Kirsten ;

Pedersen, Lone Bredo ;

Geisler, Christian H. .

BLOOD, 2011, 118 (21) :1160-1161

[40] Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study [J].

Kahl, Brad S. ;

Bartlett, Nancy L. ;

Leonard, John P. ;

Chen, Ling ;

Ganjoo, Kristen ;

Williams, Michael E. ;

Czuczman, Myron S. ;

Robinson, K. Sue ;

Joyce, Robin ;

van der Jagt, Richard H. ;

Cheson, Bruce D. .

CANCER, 2010, 116 (01) :106-114

← 1 2 3 4 5 6 7 8 9 10 →